Part, Chapter, Paragraph
1 -, 1 | over a longer period;~· Analysis of the health determinants
2 -, 1 | iii) Data description and analysis; (iv) Risk factors; (v)
3 I, 2. 1 | Figure 2.1).~ ~ ~ ~The analysis of the underlying factors
4 I, 2. 2 | updates the Commission’s first analysis of the European tourism
5 I, 2. 5 | accession countries into the analysis. The report highlights the
6 I, 2. 5 | methodology for comparative analysis and the exchange of good
7 I, 2. 10. 1 | genomics and/or in silico analysis to dissect the genetic basis
8 I, 2. 10. 1 | to the need for complex analysis in ‘omics’ technologies.~ ~
9 I, 2. 10. 1 | omics’ technologies.~ ~Analysis and exploitation of biodiversity
10 I, 2. 10. 3 | standardisation for ICT.~Analysis of the possible application
11 II, 4. 1 | eastern countries. A specific analysis made by EHEMU showed that
12 II, 4. 2 | birth and at other ages. The analysis of mortality trends is limited
13 II, 5. 1. 1 | factors, in a multivariate analysis including age, gender, smoking
14 II, 5. 2. 3 | 3. Data description and analysis~ ~
15 II, 5. 2. 3 | validated, therefore the analysis of temporal trends was not
16 II, 5. 2. 6 | reduction? A meta-regression analysis. J Am Coll Cardiol 46: 1855-
17 II, 5. 3. 2 | statutory, but cancer survival analysis is illegal.~ ~Lack of dedicated
18 II, 5. 3. 2 | cancer research in Europe; analysis and synthesis of National
19 II, 5. 3. 9 | Europe: a 2000–02 period analysis of EUROCARE-4 data. Lancet
20 II, 5. 4. 2 | physical examination and blood analysis. ~It is well known that
21 II, 5. 4. 2 | request for research and analysis through national/regional
22 II, 5. 4. 3 | 4.3 Data description and analysis~ ~Comparable data on the
23 II, 5. 4. 4 | start collecting data for an analysis of the current health status
24 II, 5. 5. 1 | 3. Data description and analysis~ ~Prevalence, incidence,
25 II, 5. 5. 1 | Europe: a gender-specific analysis of countries participating
26 II, 5. 5. 2 | 3. Data description and analysis~ ~Prevalence~ ~The prevalence
27 II, 5. 5. 2 | prevention strategies and an analysis of the socio-economic cost
28 II, 5. 5. 3 | European Union-wide data analysis and comparison of data is
29 II, 5. 5. 3 | 3. Data description and analysis~ ~Reviewed articles and
30 II, 5. 5. 3 | 3. Data description and analysis~ ~Data usually representing
31 II, 5. 5. 3 | disorders in Europe by an analysis of studies from Italy, Denmark,
32 II, 5. 5. 3 | Kingdom. Included in this analysis are psychotic disorders
33 II, 5. 5. 3 | 3. Data description and analysis~ ~Cross-sectional studies
34 II, 5. 5. 3 | as to prevent comparative analysis and do not explain major
35 II, 5. 5. 3 | prevent some comparative analysis and do not fully explain
36 II, 5. 5. 3 | 3. Data description and analysis~ ~In Europe, the incidence,
37 II, 5. 5. 3 | confirmed when limiting the analysis to prospective and retrospective
38 II, 5. 5. 3 | the different methods of analysis. Patients with severe epilepsy
39 II, 5. 5. 3 | 3. Data description and analysis~ ~Nearly 200 surveys on
40 II, 5. 5. 3 | European wide survey and analysis (Sobocki et al, 2007) revealed
41 II, 5. 5. 3 | in cost-effectiveness analysis. Health Policy and Planning
42 II, 5. 5. 3 | 3. Data description and analysis~ ~Morbidity and mortality~
43 II, 5. 5. 3 | design were selected for this analysis. No studies, however, had
44 II, 5. 5. 3 | studies, and a comparative analysis of burden-of-disease, health-related
45 II, 5. 5. 3 | on a 3-month prospective analysis. Pharmacoeconomics 14(3):
46 II, 5. 6. 3 | 3. Data description and analysis~ ~The major musculoskeletal
47 II, 5. 6. 6 | fractures of the distal forearm. Analysis of radiographic and other
48 II, 5. 7. 2 | used for epidemiological analysis to calculate incidence,
49 II, 5. 7. 3 | 3. Data description and analysis~ ~Incidence~ ~Children and
50 II, 5. 7. 5 | and a cost-effectiveness analysis in support of this contention
51 II, 5. 7. 7 | events: a pharmacoeconomic analysis linked to the PREVEND and
52 II, 5. 7. 7 | adults: a cost-effectiveness analysis. JAMA 2003;290(23):3101-
53 II, 5. 8. 3 | 3. Data description and analysis~ ~This section addresses
54 II, 5. 8. 3 | 2005).~ ~The WHO’s Large Analysis and Review of Housing and
55 II, 5. 8. 3 | et al (2007) performed an analysis of mortality in COPD patients
56 II, 5. 8. 3 | survival. In the WHO Large Analysis and Review of European Housing
57 II, 5. 8. 3 | and 1 261€ in Italy.~ ~An analysis of the Danish Patient Registry
58 II, 5. 8. 4 | determinants, in a multivariate analysis including age, gender, smoking
59 II, 5. 8. 7 | 1979-2002: a multiple cause analysis. Thorax 2006; 61: 930-934.~ ~
60 II, 5. 8. 7 | A multiple cause coding analysis. Eur Respir J 2003; 22:
61 II, 5. 8. 7 | factors, 2001: systematic analysis of population health data.
62 II, 5. 9. 3 | 3. Data description and analysis~ ~Incidence and natural
63 II, 5. 9. 4 | of the females (P=0.03). Analysis by multiple logistic regression
64 II, 5. 9. 4 | change when restricting the analysis to atopic asthma. In conclusion,
65 II, 5. 9. 7 | 2002): The AIRE Study: data analysis of 753 European children
66 II, 5. 10. 3 | 3. Data description and analysis~ ~Prevalence of food hypersensitivity~ ~
67 II, 5. 10. 7 | allergic disorders in England: analysis of national admissions data.
68 II, 5. 10. 7 | Troncone R, Wieser H (2001): Analysis and clinical effects of
69 II, 5. 11. 3 | 3. Data description and analysis~ ~Diseases of the skin are
70 II, 5. 11. 3 | piercings, Engineering Failure Analysis, 2003;10:255–263.~DV Belsito,
71 II, 5. 11. 6 | What is clear from the analysis of the available data section
72 II, 5. 12. 2 | Joinpoint regression analysis was used to identify years
73 II, 5. 12. 2 | Kim et al, 2000). This analysis chooses the best fitting
74 II, 5. 12. 2 | changes significantly. The analysis starts with the assumption
75 II, 5. 12. 2 | predicted trend in the joinpoint analysis, and symbols to represent
76 II, 5. 12. 3 | 3. Data description and analysis~ ~Graphic representations
77 II, 5. 12. 3 | from joinpoint regression analysis of cirrhosis mortality rates
78 II, 5. 12. 3 | inference on trends. Joinpoint analysis indicates that the rates
79 II, 5. 12. 3 | 3. Joinpoint regression analysis for age-standardized cirrhosis
80 II, 5. 12. 3 | 4. Joinpoint regression analysis for age-standardized cirrhosis
81 II, 5. 12. 3 | 1970-2002.~ ~This updated analysis of mortality from cirrhosis
82 II, 5. 12. 7 | 1989: age-period-cohort analysis and changing alcohol consumption.
83 II, 5. 14. 2 | used to proceed to a state analysis of trends. A critical analysis
84 II, 5. 14. 2 | analysis of trends. A critical analysis of the methodological criteria
85 II, 5. 14. 2 | the produced information analysis, research and development
86 II, 5. 14. 3 | 14.3 Data description and analysis~ ~Dental caries~ ~In a European
87 II, 5. 14. 3 | improved in the recent past. An analysis of the literature on this
88 II, 5. 14. 4 | adolescents can benefit from diet analysis and modification. Diet analysis,
89 II, 5. 14. 4 | analysis and modification. Diet analysis, along with professionally
90 II, 5. 15. 2 | is conducting a permanent analysis of published reports providing
91 II, 5. 15. 3 | 3. Data description and analysis~ ~The distribution of RD
92 II, 5. 15. 3 | expectancy is rather short. An analysis of the death certificates
93 II, 6. 1 | contains an epidemiological analysis, based on available data
94 II, 6. 3 | 3. Data description and analysis~ ~
95 II, 6. 3. 1 | reported on EU-level.~ ~The analysis of other chapters in this
96 II, 6. 3. 1 | of data for more in-depth analysis of risk factors, determinants,
97 II, 6. 4. 5 | cooperation will favour the analysis of combined information
98 II, 6. 4. 5 | system as regards methods of analysis, sanctions and reporting
99 II, 7. 3 | 7.3. Data analysis and presentation~ ~The main
100 II, 7. 4. 1 | prepared a European situation analysis regarding injuries and risk
101 II, 7. 7 | The European Situation Analysis. AdRisk Project. Helsinki,
102 II, 8. 1. 2 | general. EU-SILC allows the analysis of earnings and income levels
103 II, 8. 1. 2 | issues, the results of the analysis of the two sets of data (
104 II, 8. 1. 6 | disabilities in the EU: statistical analysis of the lfs ad hoc module
105 II, 8. 2. 1 | 3. Data description and analysis~ ~Prevalence~ ~The prevalence
106 II, 8. 2. 2 | people aged 50 or more.~ ~The analysis of the causes of blindness
107 II, 8. 2. 2 | people aged 50 or more.~ ~The analysis of the causes of blindness
108 II, 8. 2. 2 | disabilities in the eu: statistical analysis of the LFS ad hoc module
109 II, 8. 2. 3 | disabilities in the eu: statistical analysis of the LFS ad hoc module
110 II, 9. 1. 1 | must be combined with an analysis of fetal mortality, since
111 II, 9. 1. 1 | 3. Data presentation and analysis~ ~Foetal, neonatal and infant
112 II, 9. 1. 1 | hospital payment mode: an analysis based on birth certificates.
113 II, 9. 1. 2 | 3. Data description and analysis~ ~Prevalence of congenital
114 II, 9. 2. 2 | For instance, the valuable analysis of suicide rates in Europe
115 II, 9. 2. 3 | 3. Data description and analysis~ ~Infants and child (1–4
116 II, 9. 2. 6 | higher priority than the analysis of patterns of child mortality.
117 II, 9. 3. 1 | 3. Data description and analysis~ ~Premature death is frequent
118 II, 9. 3. 1 | in the 35-44 age group. Analysis of cardiovascular diseases
119 II, 9. 3. 1 | should be assessed by PSA analysis and digital examination
120 II, 9. 3. 1 | Europe: a 2000-02 period analysis of EUROCARE-4 data." The
121 II, 9. 3. 2 | 3. Data presentation and analysis~ ~Mortality~ ~The EURO-PERISTAT
122 II, 9. 3. 2 | hospital payment mode: an analysis based on birth certificates.
123 II, 9. 3. 3 | 3. Data presentation and analysis~ ~Mean age at first sexual
124 II, 9. 3. 3 | of infectious diseases. Analysis of sexual behaviour in the
125 II, 9. 3. 3 | epidemiology: Comparative analysis in France and Britain. AIDS
126 II, 9. 3. 3 | gender : a cross-cultural analysis of trends in the 20th century.
127 II, 9. 4. 3 | 3. Data description and analysis~ ~ ~By the year 2025 about
128 II, 9. 5. 3 | 3. Data description and analysis~ ~Health inequalities~ ~
129 II, 9. 5. 4 | gender awareness, where analysis of the context in which
130 III, 10. 1 | interrelationships and address them in analysis. Due to the high complexity
131 III, 10. 1 | modelling only allows the analysis of simplified scenarios
132 III, 10. 1. 1 | for by study design and analysis: e.g. matching, adjustment,
133 III, 10. 1. 3 | social cognitive theory analysis. Clin Psychol Rev 19(5):
134 III, 10. 2. 1 | 3. Data description and analysis~ ~Prevalence and mortality~ ~
135 III, 10. 2. 1 | the first comprehensive analysis of global tobacco use and
136 III, 10. 2. 1 | expected to occur. The global analysis, collated by the WHO from
137 III, 10. 2. 1 | 3. Data description and analysis~Alcohol consumption and
138 III, 10. 2. 1 | Register-Based Multilevel Analysis of 1.1 Million Men." Social
139 III, 10. 2. 1 | Grande: a methodological analysis of clinical trials of treatments
140 III, 10. 2. 1 | 3. Data description and analysis~ ~Overall estimates on the
141 III, 10. 2. 1 | 3. Data description and analysis~ ~The Burden of oral hygiene~ ~
142 III, 10. 2. 1 | relation to oral health, risk analysis focuses on the protective
143 III, 10. 2. 1 | questions. A scientific analysis of this survey has been
144 III, 10. 2. 1 | 3. Data description and analysis~ ~An analysis of a Eurobarometer
145 III, 10. 2. 1 | description and analysis~ ~An analysis of a Eurobarometer survey
146 III, 10. 2. 1(20)| In this analysis, the cut point for “sufficient
147 III, 10. 2. 1 | 3. Data description and analysis~ ~Overweight and obesity~ ~
148 III, 10. 2. 1 | morbidity and mortality. An analysis made by the Swedish Institute
149 III, 10. 2. 1 | a decade: retrospective analysis from a Glasgow Maternity
150 III, 10. 2. 4 | 3. Data description and analysis~ ~In the past twenty years,
151 III, 10. 2. 4 | focusing on the DNA/RNA analysis technology rather than on
152 III, 10. 2. 5 | 3. Data description and analysis~ ~The Barker theory links
153 III, 10. 2. 5 | status,~ ~For a detailed analysis of diseases prevalent in
154 III, 10. 3. 1 | 3. Data description and analysis~ ~Radon~ ~Current levels
155 III, 10. 3. 1 | Barns, 2005). A pooled analysis of all European epidemiological
156 III, 10. 3. 1 | and social cost-benefit analysis.~ ~The Green Paper on Future
157 III, 10. 3. 1 | lung cancer: collaborative analysis of individual data from
158 III, 10. 3. 2 | 3. Data presentation and analysis~ ~Chemical production~ ~
159 III, 10. 3. 2 | three rounds of breast milk analysis studies of dioxins coordinated
160 III, 10. 3. 2 | not be confirmed as the analysis methods were not comparable.
161 III, 10. 3. 3 | 3. Data presentation and analysis~ ~Antimicrobial resistance (
162 III, 10. 3. 4 | 3. Data description and analysis~ ~Climatic changes~ ~There
163 III, 10. 3. 4 | Commission to deepen its analysis. A new Communication is
164 III, 10. 3. 4 | not allow for a complete analysis of the costs of inaction.
165 III, 10. 3. 4 | disease surveillance, water analysis and treatment, health education
166 III, 10. 4. 1 | 3. Data description and analysis~ ~Air pollution research
167 III, 10. 4. 1 | Table 10.4.1.3. The CAFE analysis and the strategy~ ~The need
168 III, 10. 4. 1 | legislation was revealed by analysis under the CAFE programme
169 III, 10. 4. 1 | 2005b).~Following the CAFE analysis of the various scenarios,
170 III, 10. 4. 2 | EU-RAIN~European Union Risk Analysis Information Network~FAO~
171 III, 10. 4. 2 | Manufacturing Practice~HACCP~Hazard Analysis Critical Control Point~IESTI~
172 III, 10. 4. 2 | political elements of risk analysis, a reference to the precautionary
173 III, 10. 4. 2 | establishes the principles of risk analysis in relation to food and
174 III, 10. 4. 2 | the development of risk analysis principles and their subsequent
175 III, 10. 4. 2 | inter-related components of risk analysis (risk assessment, risk management
176 III, 10. 4. 2 | the third pillar of risk analysis, requires legislative action
177 III, 10. 4. 2(27)| procedures for pesticide residues analysis in food and feed, Document
178 III, 10. 4. 2 | lays down the sampling and analysis methods sampling and analysis
179 III, 10. 4. 2 | analysis methods sampling and analysis for the official control
180 III, 10. 4. 2 | lays down the sampling and analysis methods for the official
181 III, 10. 4. 2 | lays down the sampling and analysis methods of some heavy metals,
182 III, 10. 4. 2 | lays down the sampling and analysis methods of dioxins and dioxin-like
183 III, 10. 4. 2 | incongruence in reporting the analysis. Specificity and sensitivity
184 III, 10. 4. 2 | the design, collation and analysis of a series of baseline
185 III, 10. 4. 2 | The European Union Risk Analysis Information Network (EU-RAIN)
186 III, 10. 4. 2 | 3. Data description and analysis~ ~Several years ago, the
187 III, 10. 4. 2 | GMP) and of the Hazard Analysis Critical Control Point (
188 III, 10. 4. 2 | European Community.~A risk analysis procedure based on sound
189 III, 10. 4. 2 | Guidelines for risk-benefit analysis and emerging risks~ ~In
190 III, 10. 4. 2 | guidelines for “Risk-benefit analysis of foods” and for “the identification
191 III, 10. 4. 2 | emerging risks”~ ~Risk-benefit analysis~ ~The risk assessment of
192 III, 10. 4. 2 | consensus that a risk-benefit analysis should mirror the paradigm
193 III, 10. 4. 2 | well established for risk analysis, consisting of a risk-benefit
194 III, 10. 4. 2 | addition, the risk-benefit analysis should contain a means(
195 III, 10. 4. 2 | initiate a risk-benefit analysis should be made on a case-by-case
196 III, 10. 4. 2 | required to carry out such an analysis, should only be undertaken
197 III, 10. 4. 2 | why is the risk-benefit analysis being done, why do we need
198 III, 10. 4. 2 | reasons each risk-benefit analysis needs a narrative up-front
199 III, 10. 4. 2 | outcome of a risk-benefit analysis, the assumptions made for
200 III, 10. 4. 2 | made for the assessment and analysis as well as the uncertainties
201 III, 10. 4. 2 | into account, risk-benefit analysis could improve risk communication
202 III, 10. 4. 2 | whether the term “risk-benefit analysis” was the appropriate terminology,
203 III, 10. 4. 2 | terminology such as hazard-benefit analysis or risk-chance [for benefit]
204 III, 10. 4. 2 | risk-chance [for benefit] analysis for benefit may be more
205 III, 10. 4. 2 | colloquium on “Risk-benefits analysis of foods: methods and approaches”
206 III, 10. 4. 3 | 3. Data presentation and analysis~ ~Drinking water~ ~Health
207 III, 10. 4. 3 | out a framework for the analysis, planning and management
208 III, 10. 4. 3 | process for a comprehensive analysis in order to prepare possible
209 III, 10. 4. 5 | Data description and analysis~ ~ ~At present, the general
210 III, 10. 4. 5 | Data description and analysis~ ~Waste production~ ~Based
211 III, 10. 4. 5 | Figure 10.4.5.2.6. Detailed analysis of industrial and commercial
212 III, 10. 4. 5 | escape formal epidemiological analysis but are relevant for the
213 III, 10. 4. 5 | the basis of a feasibility analysis aimed at avoiding the execution
214 III, 10. 4. 5 | timing of exposures, and the analysis of all relevant environmental
215 III, 10. 5. 1 | 3. Data description and analysis~ ~As human settlements are
216 III, 10. 5. 1 | symptoms in schools: an analysis of existing information.
217 III, 10. 5. 2 | 3. Data description and analysis.~ ~Demographic and contextual
218 III, 10. 5. 2 | as well, i.e. account all analysis for the age of the respective
219 III, 10. 5. 2 | and survival from cancer: analysis of Scottish cancer registration.
220 III, 10. 5. 3 | 3.3 Data description and analysis~The burden of diseases to
221 III, 10. 6. 1 | 3. Data description and analysis~ ~Data on social support
222 III, 10. 6. 1 | and epidemiological data analysis, so that their influence
223 III, 10. 6. 1 | in the EU. A comparative analysis of the European Survey of
224 III, 10. 6. 2 | 3. Data description and analysis~ ~Among the living and working
225 III, 10. 6. 3 | published a comparative analysis of crime and safety in Europe (
226 III, 10. 6. 3 | 3. Data description and analysis~ ~Homicides: As far as homicides
227 III, 10. 6. 3 | are concerned, a detailed analysis has been carried out in
228 IV, 11. 1. 3 | point for a comparative analysis, although as shown throughout
229 IV, 11. 1. 6 | of Medicine, 2001).~ ~The analysis of payment mechanisms generally
230 IV, 11. 3. 2 | consequences to include in the analysis, how to ensure the consistent
231 IV, 11. 3. 2 | resources needed to undertake analysis. Many countries are now
232 IV, 11. 3. 2 | France cost-effectiveness analysis is used to inform decisions
233 IV, 11. 4 | multidisciplinary field of policy analysis. It studies the medical,
234 IV, 11. 4 | preferences in health economic analysis~Information and data for
235 IV, 11. 5. 4 | undertake a proper risk-benefit analysis by the transplant team.
236 IV, 11. 6. 4 | Rice and Smith 2002). An analysis of the risk adjustment schemes
237 IV, 11. 6. 4 | records), the basic unit of analysis and the variables available
238 IV, 11. 6. 4 | available for stratified analysis. This information was organised
239 IV, 11. 6. 4 | to the public (www ). The analysis of collected data showed
240 IV, 11. 6. 4 | projects.~The results of the analysis will be published on the
241 IV, 11. 6. 5 | Social Policy: a Comparative Analysis of Taxes, Tax Expenditure
242 IV, 11. 6. 5 | 41. London, Centre for Analysis of Social Exclusion, London
243 IV, 11. 6. 5 | Hakkinen U (1998): "Micro-level analysis of distributional changes
244 IV, 12. 2 | the first comprehensive analysis of global tobacco use and
245 IV, 12. 2 | expected to occur. The global analysis, compiled by WHO with information
246 IV, 12. 4 | information, research and analysis.~EU-OSHA~ ~European Agency
247 IV, 12. 5 | Develop mechanisms for analysis and dissemination, including
248 IV, 12. 5 | qualitative and quantitative analysis.~ ~3.3. Provide analysis
249 IV, 12. 5 | analysis.~ ~3.3. Provide analysis and technical assistance
250 IV, 12. 5 | platform for the collection, analysis and dissemination of data
251 IV, 13. 2. 2 | high-income countries.~· An analysis carried out by the Swedish
252 IV, 13. 3 | stems from many different analysis and particularly from the
253 IV, 13. 7. 1 | in Europe – A statistical Analysis and Overview of Current
254 IV, 13. 7. 1 | has to be provided. The analysis presented in the above-mentioned
255 IV, 13. 7. 2 | year is the result of an analysis of 25 different indicators
